While radiofrequency holds the largest share, ultrasound-based renal denervation is projected to be the fastest-growing technology segment in the coming years. Ultrasound systems offer a non-contact method of ablation, using high-frequency sound waves to target nerves deeper within the arterial wall without directly heating the artery surface. Detailed clinical outcomes for ultrasound systems are documented in the Renal Denervation Market report.

People also ask: Is ultrasound renal denervation safer than radiofrequency? What are the advantages of ultrasound-based RDN? Surgeons are increasingly attracted to this method because it can provide a more circumferential and complete denervation, which may lead to more significant and consistent blood pressure reductions in resistant patients.

Recent FDA approvals for ultrasound systems, such as ReCor Medical’s Paradise system, have provided a major boost to this segment. As more real-world evidence confirms its efficacy, ultrasound-based procedures are expected to capture a larger portion of the elective surgery market.